The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node- negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
- Author
- EIERMANN, W1 ; REZAI, M2 ; JACKISCH, C11 ; WITZEL, I12 ; EIDTMANN, H13 ; BACHINGER, A14 ; HELL, S15 ; BLOHMER, J16 ; KÜMMEL, S3 ; KÜHN, T4 ; WARM, M5 ; FRIEDRICHS, K6 ; SCHNEEWEISS, A7 ; MARKMANN, S8 ; EGGEMANN, H9 ; HILFRICH, J10
[1] Interdisciplinary Oncology Center, Munich, Germany
[2] Breast Center, Luisen-Hospital, Düsseldorf, Germany
[3] Senology Breast Care Center, Clinic Essen-Mitte, Essen, Germany
[4] Department of Gynceology and Obstetrics, Esslingen Hospital, Esslingen, Germany
[5] Department of Gynecology and Obstetrics, Holweide Hospital, Cologne, Germany
[6] Breast Center, Hamburg, Germany
[7] Section of Gynecological Oncology, National Center for Tumor Diseases University Hospital, Heidelberg, Germany
[8] Department of Gynecology and Obstetrics, University Hospital, Rostock, Germany
[9] Department of Gynecology and Obstetrics, University Hospital, Magdeburg, Germany
[10] Eilenriede Hospital, Hanover, Germany
[11] Department of Obstetrics and Gynecology and Breast center, Offenbach Hospital, Offenbach, Germany
[12] Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
[13] Department of Gynecology and Obstetrics, University Hospital, Kiel, Germany
[14] Department of Biometrics, ClinAssess GmbH, Leverkusen, Germany
[15] Medical Affairs Consulting, Speyer, Germany
[16] Department of Gynecology and Obstetrics, Sankt Gertrauden Hospital, Berlin, Germany - Source
Annals of oncology. 2013, Vol 24, Num 3, pp 618-624, 7 p ; ref : 35 ref
- ISSN
- 0923-7534
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Oxford University Press, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- adjuvant breast cancer chemotherapy node negative node positive recurrence score
- Keyword (fr)
- Cancer du sein Chimiothérapie Facteur risque Gène Génétique Noeud Précoce Recommandation Récidive Récurrence Stade précoce Traitement adjuvant Score Cancer Pathologie de la glande mammaire Pathologie du sein Traitement Tumeur maligne
- Keyword (en)
- Breast cancer Chemotherapy Risk factor Gene Genetics Node Early Recommendation Relapse Recurrence Early stage Adjuvant treatment Score Cancer Mammary gland diseases Breast disease Treatment Malignant tumor
- Keyword (es)
- Cáncer del pecho Quimioterapia Factor riesgo Gen Genética Nudo Precoz Recomendación Recaida Recurrencia Estadio precoz Tratamiento adyuvante Cáncer Glándula mamaria patología Seno patología Tratamiento Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27179409
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1093/annonc/mds512 
https://dx.doi.org/10.1093/annonc/mds512
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mds512\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:200:\"The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node- negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"618\";s:8:\"\u0000*\u0000epage\";s:3:\"624\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"EIERMANN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:8:\"REZAI, M\";i:1;s:11:\"JACKISCH, C\";i:2;s:9:\"WITZEL, I\";i:3;s:11:\"EIDTMANN, H\";i:4;s:12:\"BACHINGER, A\";i:5;s:7:\"HELL, S\";i:6;s:10:\"BLOHMER, J\";i:7;s:10:\"K\u00dcMMEL, S\";i:8;s:8:\"K\u00dcHN, T\";i:9;s:7:\"WARM, M\";i:10;s:13:\"FRIEDRICHS, K\";i:11;s:14:\"SCHNEEWEISS, A\";i:12;s:11:\"MARKMANN, S\";i:13;s:11:\"EGGEMANN, H\";i:14;s:11:\"HILFRICH, J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:200:\"The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node- negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mds512\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:200:\"The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node- negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"618\";s:8:\"\u0000*\u0000epage\";s:3:\"624\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"EIERMANN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:8:\"REZAI, M\";i:1;s:11:\"JACKISCH, C\";i:2;s:9:\"WITZEL, I\";i:3;s:11:\"EIDTMANN, H\";i:4;s:12:\"BACHINGER, A\";i:5;s:7:\"HELL, S\";i:6;s:10:\"BLOHMER, J\";i:7;s:10:\"K\u00dcMMEL, S\";i:8;s:8:\"K\u00dcHN, T\";i:9;s:7:\"WARM, M\";i:10;s:13:\"FRIEDRICHS, K\";i:11;s:14:\"SCHNEEWEISS, A\";i:12;s:11:\"MARKMANN, S\";i:13;s:11:\"EGGEMANN, H\";i:14;s:11:\"HILFRICH, J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:200:\"The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node- negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mds512\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mds512\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:200:\"The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node- negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"618\";s:8:\"\u0000*\u0000epage\";s:3:\"624\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"EIERMANN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:8:\"REZAI, M\";i:1;s:11:\"JACKISCH, C\";i:2;s:9:\"WITZEL, I\";i:3;s:11:\"EIDTMANN, H\";i:4;s:12:\"BACHINGER, A\";i:5;s:7:\"HELL, S\";i:6;s:10:\"BLOHMER, J\";i:7;s:10:\"K\u00dcMMEL, S\";i:8;s:8:\"K\u00dcHN, T\";i:9;s:7:\"WARM, M\";i:10;s:13:\"FRIEDRICHS, K\";i:11;s:14:\"SCHNEEWEISS, A\";i:12;s:11:\"MARKMANN, S\";i:13;s:11:\"EGGEMANN, H\";i:14;s:11:\"HILFRICH, J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:200:\"The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node- negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mds512\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:200:\"The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node- negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"618\";s:8:\"\u0000*\u0000epage\";s:3:\"624\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"EIERMANN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:8:\"REZAI, M\";i:1;s:11:\"JACKISCH, C\";i:2;s:9:\"WITZEL, I\";i:3;s:11:\"EIDTMANN, H\";i:4;s:12:\"BACHINGER, A\";i:5;s:7:\"HELL, S\";i:6;s:10:\"BLOHMER, J\";i:7;s:10:\"K\u00dcMMEL, S\";i:8;s:8:\"K\u00dcHN, T\";i:9;s:7:\"WARM, M\";i:10;s:13:\"FRIEDRICHS, K\";i:11;s:14:\"SCHNEEWEISS, A\";i:12;s:11:\"MARKMANN, S\";i:13;s:11:\"EGGEMANN, H\";i:14;s:11:\"HILFRICH, J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:200:\"The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node- negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mds512\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:200:\"The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node- negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"618\";s:8:\"\u0000*\u0000epage\";s:3:\"624\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"EIERMANN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:8:\"REZAI, M\";i:1;s:11:\"JACKISCH, C\";i:2;s:9:\"WITZEL, I\";i:3;s:11:\"EIDTMANN, H\";i:4;s:12:\"BACHINGER, A\";i:5;s:7:\"HELL, S\";i:6;s:10:\"BLOHMER, J\";i:7;s:10:\"K\u00dcMMEL, S\";i:8;s:8:\"K\u00dcHN, T\";i:9;s:7:\"WARM, M\";i:10;s:13:\"FRIEDRICHS, K\";i:11;s:14:\"SCHNEEWEISS, A\";i:12;s:11:\"MARKMANN, S\";i:13;s:11:\"EGGEMANN, H\";i:14;s:11:\"HILFRICH, J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:200:\"The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node- negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
